Lomakin Yakov, Belogurov Alexey, Glagoleva Irina, Stepanov Alexey, Zakharov Konstantin, Okunola John, Smirnov Ivan, Genkin Dmitry, Gabibov Alexander
Institute of Bioorganic Chemistry RAS, Moscow 117997, Russia; Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420012, Russia.
Institute of Bioorganic Chemistry RAS, Moscow 117997, Russia; Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420012, Russia; Institute of Gene Biology RAS, Moscow 119334, Russia.
Mediators Inflamm. 2016;2016:2847232. doi: 10.1155/2016/2847232. Epub 2016 Apr 28.
We have previously shown that immunodominant MBP peptides encapsulated in mannosylated liposomes (Xemys) effectively suppressed experimental allergic encephalomyelitis (EAE). Within the frames of the successfully completed phase I clinical trial, we investigated changes in the serum cytokine profile after Xemys administration in MS patients. We observed a statistically significant decrease of MCP-1/CCL2, MIP-1β/CCL4, IL-7, and IL-2 at the time of study completion. In contrast, the serum levels of TNF-α were remarkably elevated. Our data suggest that the administration of Xemys leads to a normalization of cytokine status in MS patients to values commonly reported for healthy subjects. These data are an important contribution for the upcoming Xemys clinical trials.
我们之前已经表明，包裹在甘露糖基化脂质体（Xemys）中的免疫显性髓鞘碱性蛋白（MBP）肽可有效抑制实验性自身免疫性脑脊髓炎（EAE）。在成功完成的I期临床试验框架内，我们研究了MS患者服用Xemys后血清细胞因子谱的变化。在研究结束时，我们观察到MCP-1/CCL2、MIP-1β/CCL4、IL-7和IL-2有统计学意义的下降。相比之下，TNF-α的血清水平显著升高。我们的数据表明，服用Xemys可使MS患者的细胞因子状态恢复正常，达到健康受试者通常报告的值。这些数据对即将进行的Xemys临床试验有重要贡献。
